Join

Compare · NVO vs TRVN

NVO vs TRVN

Side-by-side comparison of Novo Nordisk A/S (NVO) and Trevena Inc. (TRVN): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVO and TRVN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $191.15B, about 2311.2x TRVN ($82.7M).
  • Over the past year, NVO is down 44.3% and TRVN is up 0.0% - TRVN leads by 44.3 points.
  • NVO has hit the wire 8 times in the past 4 weeks while TRVN has been quiet.
  • NVO has more recent analyst coverage (25 ratings vs 0 for TRVN).
PerformanceNVO-11.11%TRVN+0.00%
2026-02-17+0.00%2026-06-11
MetricNVOTRVN
Company
Novo Nordisk A/S
Trevena Inc.
Price
$43.83+2.43%
$2.53-41.57%
Market cap
$191.15B
$82.7M
1M return
-6.68%
+0.00%
1Y return
-44.30%
+0.00%
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
2014
News (4w)
8
0
Recent ratings
25
0
NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

TRVN

Trevena Inc.

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Latest NVO

Latest TRVN